Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab

Maurizio Battaglia Parodi, Umberto De Benedetto, Karl Anders Knutsson, Fabrizio Scotti, Aloisa Librando, Francesco Bandello, Pierluigi Iacono

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up. Methods: A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month. Results: At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV. Conclusions: Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.

Original languageEnglish
Pages (from-to)202-204
Number of pages3
JournalJournal of Ocular Pharmacology and Therapeutics
Volume28
Issue number2
DOIs
Publication statusPublished - Apr 1 2012

Fingerprint

Choroidal Neovascularization
Retinitis Pigmentosa
Visual Acuity
Intravitreal Injections
Bevacizumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Cite this

Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab. / Battaglia Parodi, Maurizio; De Benedetto, Umberto; Knutsson, Karl Anders; Scotti, Fabrizio; Librando, Aloisa; Bandello, Francesco; Iacono, Pierluigi.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 28, No. 2, 01.04.2012, p. 202-204.

Research output: Contribution to journalArticle

Battaglia Parodi, Maurizio ; De Benedetto, Umberto ; Knutsson, Karl Anders ; Scotti, Fabrizio ; Librando, Aloisa ; Bandello, Francesco ; Iacono, Pierluigi. / Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab. In: Journal of Ocular Pharmacology and Therapeutics. 2012 ; Vol. 28, No. 2. pp. 202-204.
@article{6bbf12ca96554d1abdc808d33ecee4fa,
title = "Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab",
abstract = "Purpose: To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up. Methods: A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month. Results: At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV. Conclusions: Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.",
author = "{Battaglia Parodi}, Maurizio and {De Benedetto}, Umberto and Knutsson, {Karl Anders} and Fabrizio Scotti and Aloisa Librando and Francesco Bandello and Pierluigi Iacono",
year = "2012",
month = "4",
day = "1",
doi = "10.1089/jop.2011.0140",
language = "English",
volume = "28",
pages = "202--204",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Juxtafoveal choroidal neovascularization associated with retinitis pigmentosa treated with intravitreal bevacizumab

AU - Battaglia Parodi, Maurizio

AU - De Benedetto, Umberto

AU - Knutsson, Karl Anders

AU - Scotti, Fabrizio

AU - Librando, Aloisa

AU - Bandello, Francesco

AU - Iacono, Pierluigi

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Purpose: To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up. Methods: A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month. Results: At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV. Conclusions: Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.

AB - Purpose: To describe a case of juxtafoveal choroidal neovascularization (CNV) occurring in a patient affected by retinitis pigmentosa (RP), treated with intravitreal bevacizumab over a 12-month follow-up. Methods: A 66 year-old woman referred to our center for visual acuity deterioration was diagnosed as having classic juxtafoveal CNV associated with RP. The patient was treated with intravitreal bevacizumab, and was regularly monitored every month. Results: At the end of the 12-month follow-up, best corrected visual acuity changed from 20/200 to 20/100 in the affected eye. Five intravitreal bevacizumab injections were required to obtain the stabilization of the CNV. Conclusions: Intravitreal bevacizumab is effective in producing juxtafoveal CNV stabilization and visual acuity improvement in a patient affected by RP, over a 12-month follow-up. Future studies are required to ascertain the best therapeutic approach for CNV complicating RP.

UR - http://www.scopus.com/inward/record.url?scp=84859384378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859384378&partnerID=8YFLogxK

U2 - 10.1089/jop.2011.0140

DO - 10.1089/jop.2011.0140

M3 - Article

VL - 28

SP - 202

EP - 204

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 2

ER -